421results about "Inactivation/attenuation" patented technology

The invention discloses a separation method of a bovine ephemeral fever virus, the obtained bovine ephemeral fever virus and application of the bovine ephemeral fever virus. Belongs to the technical field of bovine ephemeral fever virus separation. The invention aims to provide an efficient and rapid method for separating the bovine ephemeral fever virus. The invention provides a method for separating bovine ephemeral fever virus, which comprises the following steps: inoculating a bovine anticoagulant sample to KC cells for culture, harvesting virus, inoculating to grow into monolayer BHK-21 cells, and carrying out passage to obtain passage cells with cytopathy of the first generation; the virus strain can also be used for screening, preparing and detecting a bovine ephemeral fever virus antibody and preparing a bovine ephemeral fever virus infected animal model.

The invention relates to the technical field of biological medicine, in particular to a hepatitis A inactivated vaccine and a preparation method thereof. Comprising the following steps: cell amplification, virus culture, virus harvesting, cell disruption, ultrafiltration concentration, inactivation, purification and finished product obtaining. The virus culture comprises the following steps: separating from excrement of a hepatitis A patient and carrying out adaptive passage to obtain a virus strain; adding a carrier into a bioreactor, sterilizing for later use, inoculating a virus strain into a collected cell suspension, and transferring into the bioreactor for culturing; the cell disruption step comprises the following steps: carrying out ultrasonic oscillation on a collected virus harvesting liquid to obtain a cell disruption liquid; trichloromethane is added for extraction and centrifugation, and supernatant virus liquid is collected; the invention provides a preparation method of a hepatitis A inactivated vaccine, which is used for preparing the efficient, safe and stable hepatitis A inactivated vaccine by optimizing virus culture and inactivation processes. The method has the advantages of high virus yield and low production cost, and is suitable for large-scale production and application.

The application discloses an isolation method of bovine epidemic fever virus and the bovine epidemic fever virus obtained by the method and application of the bovine epidemic fever virus, and belongs to the technical field of bovine epidemic fever virus isolation. The application aims to provide an efficient and rapid method for isolating bovine epidemic fever virus. The application provides the isolation method of the bovine epidemic fever virus, wherein the anticoagulated blood sample of a bovine is inoculated on KC cells for culture, the virus is harvested, the BHK-21 cells are inoculated to grow into a monolayer, and the first generation of passage cells with cytopathic effect is obtained by passage. The virus strain can also be used for screening, preparation and detection of bovine epidemic fever virus antibodies, and for preparation of an animal model infected by the bovine epidemic fever virus.

An immune-based approach for treating and preventing skin cancer by boosting T cell immunity against commensal HPV present in the skin. Accordingly, provided herein are compositions comprising: (i) a plurality of antigenic peptides, each comprising a sequence of 9 to 30 amino acids derived from a protein from a commensal human papillomavirus; (ii) a plurality of live or live-attenuated commensal human papillomaviruses; (iii) a plurality of antigenic proteins from a commensal human papillomavirus, preferably in a virus-like particle; and / or (iv) a plurality of nucleic acids encoding (a) a plurality of antigenic peptides, each comprising a sequence of 9 to 30 amino acids derived from a protein from a commensal human papillomavirus, or (b) a plurality of antigenic proteins from a commensal human papillomavirus; and optionally a T cell adjuvant that increases T cell responses to the antigenic peptides.

This application relates to a deoxyribonucleic acid and pseudovirus preservation solution, its preparation method and application. The deoxyribonucleic acid and pseudovirus preservation solution includes: a buffer solution with a final concentration of 5 mM to 50 mM, a surfactant with a volume percentage of 0.05% to 1.0%, trehalose with a final concentration of 50 mM to 500 mM, a metal ion chelator with a final concentration of 0.5 mM to 5 mM, betaine with a final concentration of 100 mM to 1000 mM, and mannitol with a mass percentage of 1% to 10%. Each specific component in the above-mentioned deoxyribonucleic acid and pseudovirus preservation solution cooperates with each other at a specific concentration, which has the effect of stabilizing the state and structure of nucleic acids. It can achieve the preservation of nucleic acids and pseudoviruses without ultra-low temperature, and can stably preserve nucleic acids and pseudoviruses for up to 12 months at 30°C without affecting subsequent detection tests.

The invention provides a porcine rotavirus type G9 (PoRV) and an application of the porcine rotavirus type G9 (PoRV). According to the present invention, the porcine rotavirus G9 type SC01 strain is separated from the porcine intestinal tract tissue, and is subjected to passage purification to obtain the porcine rotavirus G9 type SC01 strain, and the microbial preservation number of the porcine rotavirus G9 type SC01 strain is CGMCC No.46200; the isolated strain can stably proliferate on passage cells to generate typical cytopathy. The porcine rotavirus G9 type isolate has excellent immunogenicity, and a vaccine prepared from the isolate can induce piglets to generate high-level neutralizing antibodies; the ELISA kit prepared by adopting the isolated strain can be used for well detecting the porcine rotavirus G9 type antibody in serum.

The invention discloses a tetravalent influenza virus subunit vaccine and a preparation method thereof, and relates to the technical field of biology, each dose of the tetravalent influenza virus subunit vaccine comprises two influenza A viruses and two influenza B viruses, the tetravalent influenza virus subunit vaccine is prepared by virus inoculation, virus multiplication culture, allantoic fluid harvesting, clarification, inactivation, ultrafiltration concentration, splitting and ultracentrifugation purification, mixing, filtration sterilization, split charging and packaging. Inactivation comprises the following steps: adding a cross-linked carboxymethyl glucan solution into the monovalent virus harvesting liquid, adding formaldehyde, and inactivating at 5 DEG C for 45 hours; then genipin is mixed into the virus liquid, the stirring speed is 200 rpm, the stirring time is 8 h under the conditions that the pH is 7.2 and the temperature is 25 DEG C, residues of free methanol can be further reduced, migration of small molecules is inhibited, and the long-term storage stability is guaranteed.

Disclosed herein are compositions and methods for eliciting an immune response against both influenza virus and coronavirus. Provided herein are compositions and methods of use thereof, the compositions comprising (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, where the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, where each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

The invention relates to a genome large fragment deleted duck adenovirus B2 strain and application thereof, the duck adenovirus B2 strain is duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19, and is preserved in China Center for Type Culture Collection on September 26, 2025, and the preservation number is CCTCC NO: V202568. Compared with the duck adenovirus B2 strain BGMH, the duck adenovirus B2 strain has a deletion region between ORF20 and ORF53 genes, and the duck adenovirus B2 strain is deleted by 7422 bp. According to the invention, the duck adenovirus B2 strain with the genome deleted in large fragment is found for the first time, and the deletion region of the virus is a good site for inserting an exogenous gene, so that the duck adenovirus B2 DAdV-B2 / delta ORF55-ORF19 can be used as a good virus vector to construct a recombinant virus, and the constructed recombinant virus can be stably inherited; the method can be applied to waterfowl novel recombinant virus vector vaccine research and development, waterfowl basic scientific research, gene virus vector delivery and the like, and has wide application prospect and value.

The present invention provides influenza viruses that exhibit enhanced growth in Vero cells. The influenza viruses include PB1, PB2, PA, NP, and NS gene segments that encode proteins having amino acid sequences that include selected amino acids. Optionally, at least one of the PB1, PB2, and PA gene segments includes a promoter cytosine to uracil mutation at nucleotide position 4. The present invention also provides pharmaceutical formulations containing the influenza viruses, methods for inducing an immune response in a mammal by administering the influenza viruses to a mammal, and methods for producing influenza viruses.

The invention provides a novel bovine nodular skin disease virus LSDV-125 strain and application thereof in vaccine preparation, and belongs to the technical field of virology. The problem that a novel vaccine strain which is clear in genetic background, stably weakened in virulence and capable of inducing broad-spectrum immune response is urgently needed is solved. The invention relates to a sheep pox virus strain, in particular to a sheep pox virus LSDV-125 which is named sheep pox virus LSDV-HLJ-2023, has the preservation number of CCTCC (China Center for Type Culture Collection) NO: V202537, and is preserved in China Center for Type Culture Collection on May 13, 2025. The method is mainly used for developing efficient and safe attenuated live vaccines.

The invention discloses an akabane virus inactivated vaccine preparation method, which comprises: carrying out Vero cell passage in a cell bottle, taking well growing cells until the cells grow to 80-90%, adding into a DMEM culture medium containing 10% of fetal calf serum, taking out the cells growing to 80-90% and having a good state, adding akabane virus CH-JL-01-2022 according to a volume ratio of 0.1%, and carrying out culture at a temperature of 80-90 DEG C so as to obtain the akabane virus inactivated vaccine. Culturing for 2-3 days in an incubator with the temperature of 37 DEG C and 5% CO2; the method comprises the following steps: preparing 0.25 M BEI, 0.1 M BPL and a 40% formaldehyde solution as inactivators, setting five concentration gradients according to the volume ratios of 0.01%, 0.05%, 0.1% and 0.5%, and collecting after 6 hours, 12 hours, 24 hours, 36 hours and 48 hours after adding; the screening of the akabane virus inactivation conditions according to the types, concentrations and inactivation time of inactivators finds that 0.5% formaldehyde shows a complete inactivation effect after inactivation for 36 hours. The inactivated virus liquid is mixed with MONTANIDETM ISA 201, an ImjectI aluminum adjuvant and a manganese adjuvant according to the volume ratio of 1: 1, and then immunization is carried out, and the protection effect of the ImjectI aluminum adjuvant is found to be optimal.

The invention relates to a preparation method of a Vero cell influenza virus vaccine, and belongs to the technical field of virus culture. In the culture of the influenza virus, red algae protein and soybean protein hydrolysate are added into a culture medium at the same time, the red algae protein and soybean protein hydrolysate are subjected to low-temperature ammonium sulfate precipitation and PD-10 desalination column purification, natural conformation is kept, integrin-FAK-Src and IGF-1R signal channels can be activated, and cell adhesion and proliferation are promoted; the latter contains soybean protein isolate, polysaccharide and RGD motif peptide, and can form an adhesion film on a substrate and mediate adhesion through integrin. According to the invention, the Vero cells and the recombinant plasmid are combined to improve cell adherence, metabolic homeostasis and oxidation resistance, so that the Vero cells grow at high density and efficiently replicate influenza viruses under a serum-free condition, the virus titer (TCID50) reaches 8.5 log10 / mL, and the Vero cells and the recombinant plasmid are suitable for industrial vaccine production.

The invention discloses an aptamer chimera constructed on the basis of click chemistry and application of the aptamer chimera. The aptamer chimera comprises a first sequence and a second sequence which are coupled through the click chemistry reaction, the first sequence comprises a nucleic acid aptamer of a targeted target protein, and the second sequence comprises a signal peptide containing a lysosome sorting motif. The aptamer chimera disclosed by the invention does not depend on the expression of LTRs on a specific cell surface, and has a relatively good degradation effect and specificity on target protein.

The invention relates to an application of a THBS4 inhibitor in preparation of a medicine for preventing and / or treating pulmonary arterial hypertension. Three pulmonary arterial hypertension rat models (a hypoxia induction model, a hypoxia combined SUGEN induction model and a monocrotaline induction model) are constructed, the expression change of THBS4 is verified through qRT-PCR and western blot, and the correlation between the expression level of THBS4 and pulmonary arterial hypertension is verified in combination with in-vitro cell experiments and in-vivo intervention. Results show that THBS4 is remarkably up-regulated in pulmonary arteries of the three models, the expression level of THBS4 is positively correlated with the severity of diseases, and THBS4 is an important regulatory factor for promoting vascular remodeling in pulmonary arterial hypertension. In vivo, by knocking down THBS4, pulmonary vascular remodeling and right ventricular hypertrophy are remarkably relieved, and it is prompted that THBS4 inhibitors show good application prospects in the aspect of preventing and / or treating pulmonary arterial hypertension.

The invention belongs to the field of drug antivirus, and particularly discloses broad-spectrum antiviral application of punicalagin, the punicalagin has a structure shown in a formula 1, is good in stability and low in biological toxic and side effects, and can be used for developing novel broad-spectrum antiviral drugs.

Provided in the present application are an RNA-guided endonuclease system and the use thereof in gene editing. The endonuclease complex comprises an RNA-guided endonuclease and RNA, wherein the RNA-guided endonuclease comprises an amino acid sequence selected from SEQ ID NOs: 1-57 and SEQ ID NOs: 150-191, guide RNA comprises RNA associated with the RNA-guided endonuclease and targeting RNA, the RNA associated with the RNA-guided endonuclease comprises the sequence of any one of SEQ ID NOs: 58-114 and SEQ ID NOs: 192-233, and the targeting RNA is at the 3'-end of the RNA associated with the RNA-guided endonuclease and is identical or complementary to the targeting sequence of a genome of interest. The endonuclease complex of the present application can be used for efficient gene cleavage and gene editing.

The present invention provides a vaccine composition comprising a therapeutically effective amount of whole influenza virus, split influenza virus, virus like particle (VLP) or a combination thereof wherein one or more surface viral glycoproteins of the whole influenza virus, split influenza virus or VLP is partially glycosylated; and wherein the whole influenza virus and the split influenza virus has been attenuated or inactivated. The present invention also provides a method of preparation of the vaccine comprising the steps of injecting working virus seed with an inhibitor of the mannosidase into embryonated chicken egg to inoculate the embryonated chicken egg; incubating the inoculated embryonated chicken egg to propagate the working vims; harvesting allantonic fluids from the inoculated embryonated chicken egg; concentrating and clarifying the harvested allantonic fluids; purifying the concentrated and clarified allantonic fluids using sucrose density centrifugation; applying deglycosylation enzyme to the purified allantonic fluid to partially glycosylate viral surface glycoprotein of the propagated vims within the purified allantonic fluid; removing deglycosylation enzyme from whole vims with partially glycosylated viral surface glycoprotein; and inactivating the vims. The present invention further provides a method of treatment for prevention of influenza infection comprising the step of administering any embodiment of the vaccine of the present invention to a subject.

The invention relates to the technical field of virus antigens, and particularly discloses an inactivation method for improving the recovery rate of enterovirus antigens. The method disclosed by the invention specifically comprises the following steps: adding a protective agent with the final concentration of 50-250 [mu] g / ml into purified enterovirus liquid; after fully and uniformly mixing, stirring and incubating the mixed solution; the protective agent is prepared by mixing TritionX-100, arginine and lysine; the incubation temperature is 25-40 DEG C, and the incubation time is 4-12 hours; then adding a formaldehyde solution until the final concentration is 180-220 mu g / ml, and inactivating for 68-76 hours under the condition that the temperature is 35-39 DEG C, so as to obtain an inactivated vaccine; and finally, washing and filtering the inactivated solution to remove TritionX-100 and formaldehyde in the sample. According to the technical scheme, the recovery rate of the antigen in the inactivation solution is greatly improved, and the residual quantity of TritionX-100 and formaldehyde is small.

The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain, which comprises a genome sequence shown in SEQ ID NO: 1. The attenuated strain comprises one or more genetic modifications of the sequence SEQ ID NO: 1, and the genetic modifications reduce the virulence of the strain.

A CD1 peptide-epitope for use in the treatment of a disease causedby an intracellular pathogen, the method for the identification ofthis CD1 peptide epitope, the pharmaceutical kit comprising thisCD1 peptide epitope and the method to treat a patient against adisease caused by an intracellular pathogen or to prevent suchinfection, based on vaccination with this CD1 peptide-epitope.

The present invention provides materials and methods for viral engineering, including materials and methods for producing vectors and viral particles useful, for example, for gene therapy.

The present specification discloses methods of inactivating a lipid-coat containing virus and proteins essentially free of a lipid-coat containing virus obtained from such methods.

To provide compositions and methods related to mutant viruses, and in particular, mutant influenza viruses.SOLUTION: The mutant virus disclosed herein includes mutant M2 sequences and mutant BM2 sequences, and are useful in immunogenic compositions, e.g., as tetravalent vaccines. Further disclosed herein are methods, compositions, and cells for propagating the viral mutants, and methods, devices, and compositions related to vaccination.SELECTED DRAWING: Figure 1

The present disclosure provides a method for treating inflammatory diseases, particularly age-related inflammatory diseases, in a mammalian subject in need thereof, comprising an effective amount of a virus-like particle comprising viral structural proteins and a galectin-3 antigen, and a composition or vaccine comprising same for that purpose.

The high pathogenicity of the rift valley fever virus limits the research on the pathogenic mechanism and prevention, control and treatment products of the rift valley fever virus, the offspring replication-deficient virus particles are successfully saved through a reverse genetic manipulation technology, and the virus particles do not have the capacity of multiple rounds of infection on common cells; stable replication and passage can only be realized in a cell line for providing exogenous envelope glycoprotein; in addition, the virus particle carries an exogenous indication protein and can indicate cell infection. The Rift Valley fever virus-like particle provided by the invention can be used as a Rift Valley fever biosafety secondary laboratory research platform, the establishment of the virus particle greatly simplifies tedious procedures in the Rift Valley fever virus research process, and paves a way for screening of Rift Valley fever virus neutralizing antibodies, research and development of candidate vaccines and research of pathogenic mechanisms of the Rift Valley fever viruses.

The present invention relates to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation to cysteine at amino acid position 267. Further, the present invention relates to immunogenic compositions comprising an avian coronavirus having such spike proteins.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

A cassette for the delivery of one or more mRNA is provided, the cassette comprising a 5' UTR, a Nodamura replicon, a ribosomal skipping polynucleotide, the one or more mRNA, a plant virus assembly origin polynucleotide ("OAS"), and a 3' UTR. In one aspect, the cassette further comprises a 5'mRNA cap. In a yet further aspect, the cassette does not comprise a poly A tail.